Last reviewed · How we verify
Conventional Vincristine
Conventional Vincristine is a Vinca alkaloid Small molecule drug developed by Universität des Saarlandes. It is currently in Phase 3 development for Acute lymphoblastic leukemia (ALL), Hodgkin lymphoma, Non-Hodgkin lymphoma.
Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, causing cell cycle arrest in metaphase and triggering apoptosis in cancer cells.
Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, causing cell cycle arrest in metaphase and triggering apoptosis in cancer cells. Used for Acute lymphoblastic leukemia (ALL), Hodgkin lymphoma, Non-Hodgkin lymphoma.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Conventional Vincristine |
|---|---|
| Sponsor | Universität des Saarlandes |
| Drug class | Vinca alkaloid |
| Target | Tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vincristine inhibits the polymerization of tubulin dimers into microtubules, which are essential for mitotic spindle formation during cell division. By preventing microtubule assembly, the drug traps cells in metaphase, leading to mitotic arrest and subsequent programmed cell death. This mechanism is particularly effective against rapidly dividing cancer cells.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Rhabdomyosarcoma
- Neuroblastoma
- Wilms tumor
Common side effects
- Peripheral neuropathy
- Neutropenia
- Constipation
- Alopecia
- Nausea/vomiting
- Anemia
- Jaw pain
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (PHASE1, PHASE2)
- Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (PHASE3)
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional Vincristine CI brief — competitive landscape report
- Conventional Vincristine updates RSS · CI watch RSS
- Universität des Saarlandes portfolio CI
Frequently asked questions about Conventional Vincristine
What is Conventional Vincristine?
How does Conventional Vincristine work?
What is Conventional Vincristine used for?
Who makes Conventional Vincristine?
What drug class is Conventional Vincristine in?
What development phase is Conventional Vincristine in?
What are the side effects of Conventional Vincristine?
What does Conventional Vincristine target?
Related
- Drug class: All Vinca alkaloid drugs
- Target: All drugs targeting Tubulin
- Manufacturer: Universität des Saarlandes — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute lymphoblastic leukemia (ALL)
- Indication: Drugs for Hodgkin lymphoma
- Indication: Drugs for Non-Hodgkin lymphoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing